



Bulletin from the Extra General Meeting of Redsense Medical AB (publ) on April 24, 2025

Redsense Medical AB (publ) ("Redsense Medical" or the "Company") held an Extra General Meeting on Thursday April 24, 2025, at which the following main resolutions were adopted. All resolutions were passed with the required majority. For detailed information regarding the content of the resolutions, please refer to the notice of the EGM available on the Company's website www.redsensemedical.com.

Due to unforeseen events in early 2025, the Company did not have a quorate Board of Directors, which was why the Board called this Extraordinary General Meeting. The Nomination Committee intends to present shortly a proposal for a new permanent Board of Directors to be elected at the Annual General Meeting, which is planned to be held at the end of May 2025. Prior to this Extraordinary General Meeting, the Board of Directors consisted of Susanne Olauson (Chairman) and Martin Roos, both of whom are elected for the period until the next Annual General Meeting.

Resolution on the number of Directors (item 7)

The Meeting resolved that the Board of Directors, for the period until the end of the next Annual General Meeting, shall consist of three members elected by the General Meeting with no deputies.

Election of Director (item 8)

The Meeting resolved to elect the Company's CFO, Peter Larsson, as a new member of the Board of Directors, for the period until the end of the next Annual General Meeting.

It was noted that the Board of Directors thus now consist of Susanne Olauson, Martin Roos and Peter Larsson.

More information about the newly elected board member is available on the Company's website, www.redsensemedical.com.

Contact information

For more information, please contact:
Sebastien Bollue CEO
Telephone: +46 ((0) 72-171 1264
E-mail: [sebastien.bollue \(at\) redsensemedical.com](mailto:sebastien.bollue@redsensemedical.com)

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).